

scheduled to speak in the order in which they register and grouped by new technology applicant. Therefore, individuals who want to be presenters must register and submit their agenda item(s) by the date specified in the "DATES" section. Once the agenda is completed, it will be posted on the IPPS Web site at [http://www.cms.hhs.gov/AcuteInpatientPPS/08\\_newtech.asp#TopOfPage](http://www.cms.hhs.gov/AcuteInpatientPPS/08_newtech.asp#TopOfPage). Comments from participants will be heard (time permitting) after the completion of the presentations.

For presenters or participants who cannot come to CMS for the meeting, an open toll-free phone line, (888) 577-8990, has been made available. If you are calling in, the operator will ask you for the conference code. The conference code is "New Tech." In addition, written comments will also be accepted and presented at the meeting if they are received by the date specified in the "DATES" section. Written comments may also be submitted after the meeting. If the comments are to be considered before the publication of the proposed rule, the comments must be received by the date specified in the "DATES" section.

### III. Registration Instructions

The Division of Acute Care in CMS is coordinating the meeting registration for both the Informational Workshop and Town Hall Meeting. While there is no registration fee, individuals must register to attend the Town Hall Meeting on substantial clinical improvement and for the Informational Workshop (two separate registrations).

Individuals may present their comments for the Town Hall Meeting either in person or by phone. These individuals must register and submit their agenda item(s) by the date specified in the "DATES" section. All other participants for the Town Hall Meeting must register by the date specified in the "DATES" section.

All registrants will receive confirmation with instructions for arrival at the CMS complex (persons who register on-line will receive this confirmation upon completion of registration process and should print the confirmation and bring it with them to the meeting). Because of limited meeting space and our desire to maintain an accurate count of registrants who plan to come to CMS, we prefer that these persons register on-line. In addition, we would prefer that registrants who plan to participate by phone register by phone or fax.

#### A. On-line Registration

Registration may be completed on-line at the following Web address: [http://www.cms.hhs.gov/AcuteInpatientPPS/08\\_newtech.asp#TopOfPage](http://www.cms.hhs.gov/AcuteInpatientPPS/08_newtech.asp#TopOfPage). Select the link "Register to Attend the New Technology Town Hall Meeting" and/or "Register to attend the New Technology Informational Workshop." After completing the registration, on-line registrants should print the confirmation page and bring it with them to the meeting(s).

#### B. Registration by Phone, Fax or Mail

Registration for both meetings may also be completed by contacting Tiffany Swygert at (410) 786-4642 or Michael Treitel at (410) 786-4552. Registration may also be completed by fax to the attention of the New Technology Team at (410) 786-0169. If registration is completed by phone fax or mail, please provide your name, address, and telephone number, meetings, which you are registering for Town Hall Meeting and/or Informational Workshop and, if available, e-mail address and fax number. Please send mail in registration to address specified in the "ADDRESSES" section.

### IV. Security Information

Because this meeting will be located on Federal property, for security reasons, any persons wishing to attend this Informational Workshop and Town Meeting must register by close of business on February 15, 2007. Individuals who have not registered in advance will not be allowed to enter the building to attend the meeting. Seating capacity is limited to the first 250 registrants.

The on-site check-in for visitors will begin at 8:30 a.m. Please allow sufficient time to go through the security checkpoints. It is suggested that you arrive at central building by 8:30 a.m. so that you will have enough time to check-in before the session begins. Individuals that will only attend the Town Hall Meeting must check-in at 1 p.m. Security measures will include inspection of vehicles, inside and out, at the entrance to the grounds. In addition, all persons entering the building must check in by name, provide a government-issued identification, and pass through a metal detector. All items brought to CMS, whether personal or for the purpose of demonstration or to support a presentation, including items such as laptops, cell phones, and palm pilots, are subject to physical inspection. Participants attending the Informational Workshop will be able to

attend the Town Hall meeting without an additional check-in unless they exit the building. In this case, a participant will need to repeat the security check-in and procedures.

**Authority:** Section 503 of Public Law 108-173.

(Catalog of Federal Domestic Assistance Program No. 93.773, Medicare—Hospital Insurance; and Program No. 93.774, Medicare—Supplementary Medical Insurance Program)

Dated: November 30, 2006.

**Leslie V. Norwalk,**

*Acting Administrator, Centers for Medicare & Medicaid Services.*

[FR Doc. 06-9838 Filed 12-20-06; 8:45 am]

BILLING CODE 4120-01-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Administration for Children and Families

**AGENCY:** Administration for Native Americans (ANA), HHS.

**ACTION:** Notice of Public Comment on the Proposed Adoption of ANA Program Policies and Procedures; Correction

**SUMMARY:** Pursuant to section 814 of the Native American Programs Act of 1974 (the Act) 42 U.S.C. 2992b-1, ANA herein describes its proposed interpretive rules, statements of general policy and rules of agency procedure or practice in relation to the Social and Economic Development Strategies (hereinafter referred to as SEDS), Native Language Preservation and Maintenance (hereinafter referred to as Native Language), Environmental Regulatory Enhancement (hereinafter referred to as Environmental), Environmental Mitigation (hereinafter referred to as Mitigation), Improving the Well-Being of Children—Native American Health Marriage Initiative (hereinafter referred to as Healthy Marriage) programs and any Special Initiatives. Under the statute, ANA is required to provide members of the public an opportunity to comment on proposed changes in interpretive rules, statements of general policy and rules of agency procedure or practice and to give notice of the final adoption of such changes at least thirty (30) days before the changes become effective. This Notice also provides additional information about ANA's plan for administering the programs.

**FOR FURTHER INFORMATION CONTACT:** Sheila K. Cooper, Director of Program Operations, toll-free at (877) 922-9262.

In the **Federal Register** Notice published on November 21, 2006 (Vol.

71, No. 224), make the following addition under *Additional Information*:

#### VI. ANA Administrative Policy

ANA is issuing a policy clarification statement. Currently, ANA has an administrative policy that states "An applicant can have only one active Social and Economic Development Strategies (SEDS) grant operating at any given time." In addition to the regular SEDS competition, ANA currently conducts two special initiative awards programs under Section 803(a) of the Native American Programs Act, 42 U.S.C. 2991b(a). The two additional programs funded under the SEDS Catalog of Federal Domestic Assistance number 93.612 are the SEDS-Alaska and the Improving the Well-Being of Children: Native American Health Marriage Initiative (NAHMI). By issuing this statement, ANA is reinforcing the policy that applicants may submit only one application for SEDS or one application for NAHMI, but not for both. ANA will only accept for funding competition the first application submitted. If two applications are received from the same applicant at the same time, the applicant will be notified, prior to an eligibility determination, that only one application will be accepted. ANA will continue to enforce its policy that grantees cannot receive two or more grant awards under the SEDS category.

Dated: December 9, 2006.

#### Quanah Crossland Stamps,

*Commissioner, Administration for Native Americans.*

[FR Doc. 06-9834 Filed 12-21-06; 8:45 am]

BILLING CODE 4184-01-M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

#### Advisory Committee for Reproductive Health Drugs; Notice of Meeting

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

*Name of Committee:* Advisory Committee for Reproductive Health Drugs.

*General Function of the Committee:* To provide advice and recommendations to the agency on FDA's regulatory issues.

*Date and Time:* The meeting will be held on January 23, 2007, from 8:30 a.m. to 6 p.m. and on January 24, 2007, from 8:30 a.m. to 5:00 p.m.

*Location:* Food and Drug Administration, Center for Drug Evaluation and Research Advisory Committee Conference Room, rm. 1066, 5630 Fishers Lane, Rockville, MD.

*Contact Person:* Teresa Watkins, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane (for express delivery, 5630 Fishers Lane, rm. 1093), Rockville, MD 20857, 301-827-7001, FAX: 301-827-6776, e-mail: [Teresa.Watkins@fda.hhs.gov](mailto:Teresa.Watkins@fda.hhs.gov) FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 3014512537. Please call the Information Line for up-to-date information on this meeting.

*Agenda:* On January 23 and 24, 2007, presentations and committee discussions will address current issues which influence the consideration for approval of oral and non-oral (i.e., transdermal and intravaginal) hormonal contraceptive drug products. Implantable and injectable hormone products will not be discussed. Issues for discussion will include clinical trial design, expectations for efficacy and safety outcomes, and measures of acceptability of the product to the user, including cycle control. FDA intends to make background material available to the public no later than 1 business day before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA's Web site after the meeting. Background material is available at <http://www.fda.gov/ohrms/dockets/ac/acmenu.htm>, click on the year 2007 and scroll down to the appropriate advisory committee link.

*Procedure:* Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person on or before January 12, 2007. Oral presentations from the public will be scheduled between approximately 10 a.m. and 12 noon on January 24, 2007. Those desiring to make formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make

their presentation on or before January 5, 2007. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by January 8, 2007.

Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Teresa Watkins at least 7 days in advance of the meeting.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: December 15, 2006.

**Randall W. Lutter,**

*Associate Commissioner for Policy and Planning.*

[FR Doc. E6-21949 Filed 12-21-06; 8:45 am]

BILLING CODE 4160-01-S

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. 2006D-0172]

#### Guidance for Clinical Investigators, Institutional Review Boards, and Sponsors; Process for Handling Referrals to Food and Drug Administration Under 21 CFR 50.54: Additional Safeguards for Children in Clinical Investigations

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing the availability of a guidance entitled "Guidance for Clinical Investigators, Institutional Review Boards, and Sponsors; Process for Handling Referrals to FDA Under 21 CFR 50.54: Additional Safeguards for Children in Clinical Investigations." This guidance is intended to assist clinical investigators, Institutional Review Boards (IRBs), sponsors, and other interested parties in understanding FDA's process for handling clinical investigations that include children as subjects and that